Market Summary
USD119.55+1.58
Market Closed1.34%
SRPT Stock Price
SRPT RSI Chart
SRPT Valuation
SRPT Price/Sales (Trailing)
SRPT Profitability
SRPT Fundamentals
SRPT Revenue
SRPT Earnings
Price Action
52 Week Range
159.89
(Low)(High)
Last 7 days
-0.1%
Last 30 days
5.1%
Last 90 days
4.8%
Trailing 12 Months
8.5%
SRPT Financial Health
SRPT Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for SRPT
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-14 | Chambers Michael Andrew | bought | 1,092,430 | 109 | 9,979 | - |
2023-08-11 | Chambers Michael Andrew | bought | 2,559,270 | 108 | 23,686 | - |
2023-08-10 | Chambers Michael Andrew | bought | 3,701,070 | 106 | 34,867 | - |
2023-08-04 | Wigzell Hans Lennart Rudolf | acquired | 435,450 | 29.03 | 15,000 | - |
2023-08-04 | Wigzell Hans Lennart Rudolf | sold | -1,600,800 | 106 | -15,000 | - |
2023-06-01 | Brown Ryan Edward | sold (taxes) | -11,000 | 123 | -89.00 | evp, general counsel |
2023-03-30 | Arif Bilal | sold (taxes) | -41,954 | 136 | -307 | chief tech ops officer |
2023-03-08 | Rodino-Klapac Louise | sold (taxes) | -139,709 | 153 | -912 | head of r&d, cso |
2023-03-08 | Arif Bilal | sold (taxes) | -48,101 | 153 | -314 | chief tech ops officer |
2023-03-08 | Brown Ryan Edward | sold (taxes) | -97,275 | 153 | -635 | svp, general counsel |
Which funds bought or sold SRPT recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-13 | CGC Financial Services, LLC | new | - | 104,557 | 104,557 | 0.07% |
2023-09-12 | Farther Finance Advisors, LLC | unchanged | - | -443 | 2,176 | -% |
2023-08-29 | EFG Asset Management (Americas) Corp. | added | 16.23 | -8,219 | 231,330 | 0.05% |
2023-08-25 | Yarbrough Capital, LLC | new | - | 319,511 | 319,511 | 0.02% |
2023-08-24 | PERCEPTIVE ADVISORS LLC | reduced | -68.92 | -26,669,500 | 9,284,590 | 0.27% |
2023-08-23 | WOLVERINE TRADING, LLC | reduced | -71.17 | -3,338,190 | 1,041,810 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | reduced | -34.78 | -1,016,600 | 1,202,460 | 0.01% |
2023-08-22 | Asset Dedication, LLC | unchanged | - | -12,000 | 57,000 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -16.52 | -1,041,320 | 2,357,610 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 44.27 | 377,000 | 2,272,000 | 0.02% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Sarepta Therapeutics
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | sands capital management, llc | 2.5% | 2,151,378 | SC 13G/A | |
| Feb 10, 2023 | janus henderson group plc | 6.9% | 6,028,016 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.15% | 8,033,264 | SC 13G/A | |
| Feb 01, 2023 | blackrock inc. | 6.3% | 5,557,234 | SC 13G/A | |
| Feb 14, 2022 | sands capital management, llc | 6.16% | 5,364,627 | SC 13G | |
| Feb 11, 2022 | janus henderson group plc | 8.3% | 7,245,862 | SC 13G | |
| Feb 10, 2022 | vanguard group inc | 9.54% | 8,311,108 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 6.1% | 5,285,234 | SC 13G/A | |
| Aug 10, 2021 | capital research global investors | 4.8% | 3,842,491 | SC 13G/A |
Recent SEC filings of Sarepta Therapeutics
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Aug 15, 2023 | 4 | Insider Trading | |
| Aug 14, 2023 | 4 | Insider Trading | |
| Aug 11, 2023 | 4 | Insider Trading | |
| Aug 08, 2023 | 4 | Insider Trading | |
| Aug 04, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 02, 2023 | S-8 | Employee Benefits Plan | |
| Aug 02, 2023 | 10-Q | Quarterly Report | |
| Jun 22, 2023 | 8-K | Current Report | |
| Jun 22, 2023 | 8-K | Current Report |
Peers (Alternatives to Sarepta Therapeutics)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABBV | 271.1B | 56.0B | 3.50% | 10.46% | 31.22 | 4.84 | -2.31% | -31.27% |
BGNE | 258.4B | 1.8B | -3.35% | 26.15% | -149.17 | 142.72 | 69.45% | 14.65% |
VRTX | 91.3B | 9.5B | 1.11% | 26.35% | 27.14 | 9.61 | 13.83% | 5.33% |
REGN | 88.1B | 12.7B | -2.05% | 20.27% | 20.49 | 6.95 | -10.94% | -24.40% |
ALNY | 21.7B | 1.2B | -8.20% | -15.77% | -20.42 | 17.55 | 39.94% | -8.44% |
SRPT | 11.2B | 1.0B | 5.15% | 8.54% | -12.29 | 11.11 | 20.15% | -79.16% |
UTHR | 10.5B | 2.1B | -3.19% | 8.81% | 12.04 | 4.97 | 18.01% | 38.16% |
| MID-CAP | ||||||||
BPMC | 3.0B | 225.6M | 0.06% | -27.49% | -5.4 | 13.27 | -2.11% | 21.02% |
MDGL | 2.9B | - | -11.82% | 158.82% | -8.93 | - | - | -28.88% |
RARE | 2.6B | 402.9M | 1.47% | -16.95% | -3.63 | 6.49 | 20.50% | -42.46% |
MRTX | 2.1B | 27.2M | -3.08% | -49.09% | -2.89 | 78.22 | - | -14.43% |
| SMALL-CAP | ||||||||
CYTK | 3.1B | - | -6.35% | -39.40% | -7.31 | 33.28 | 34.30% | -149.91% |
CPRX | 1.3B | 302.9M | -15.88% | -2.65% | 11.18 | 4.26 | 77.72% | 112.02% |
MGNX | 289.9M | 152.5M | -10.34% | 48.10% | 38.91 | 1.9 | 127.84% | 103.41% |
CRBP | 28.7M | - | 0.62% | 3389.00% | -0.62 | - | - | -31.51% |
Sarepta Therapeutics News
Returns for SRPT
Cumulative Returns on SRPT
9.6%
10-Year Cumulative Returns
10.1%
7-Year Cumulative Returns
-4.1%
5-Year Cumulative Returns
-5.8%
3-Year Cumulative Returns
Risks for SRPT
What is the probability of a big loss on SRPT?
99.2%
Probability that Sarepta Therapeutics stock will be more than 20% underwater in next one year
85.8%
Probability that Sarepta Therapeutics stock will be more than 30% underwater in next one year.
39.2%
Probability that Sarepta Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does SRPT drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Sarepta Therapeutics was unfortunately bought at previous high price.
Drawdowns
Financials for Sarepta Therapeutics
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 2.8% | 1,003,434,000 | 975,683,000 | 933,013,000 | 876,047,000 | 835,184,000 | 765,786,000 | 701,887,000 | 645,564,000 | 600,082,000 | 573,356,000 | 540,099,000 | 495,074,000 | 450,191,000 | 407,496,000 | 380,833,000 | 365,135,000 | 344,580,000 | 323,441,000 | 301,034,000 | 273,896,000 | 241,364,000 |
| Costs and Expenses | -3.2% | 1,513,229,000 | 1,563,091,000 | 1,469,214,000 | 1,411,228,000 | 1,273,468,000 | 1,160,512,000 | 1,161,597,000 | 1,170,177,000 | 1,227,305,000 | 1,171,358,000 | 1,104,262,000 | 1,118,740,000 | 1,060,379,000 | 1,154,698,000 | 1,086,396,000 | 979,842,000 | 905,796,000 | 712,717,000 | 644,662,000 | 501,308,000 | 444,584,000 |
| S&GA Expenses | -7.3% | 454,543,000 | 490,295,000 | 451,421,000 | 408,998,000 | 365,338,000 | 283,369,000 | 282,660,000 | 290,651,000 | 304,897,000 | 306,238,000 | 317,875,000 | 313,253,000 | 313,309,000 | 307,014,000 | 284,812,000 | 267,608,000 | 245,223,000 | 224,986,000 | 207,761,000 | 175,762,000 | 150,894,000 |
| R&D Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 436,610,000 | 446,192,000 | 401,843,000 | 300,077,000 | 247,732,000 |
| EBITDA | 100.0% | - | -1,016,324,000 | -603,681,000 | -611,595,000 | -404,838,000 | -252,225,000 | -317,406,000 | -384,177,000 | -538,655,000 | -611,786,000 | -466,207,000 | -517,648,000 | -453,595,000 | -585,552,000 | -652,664,000 | - | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -1.04 | -0.65 | -0.70 | -0.48 | -0.33 | -0.45 | -0.60 | -0.90 | -1.07 | -0.86 | -1.05 | -1.01 | -1.44 | -1.71 | - | - | - | - | - | - |
| Interest Expenses | -38.5% | 24,455,000 | 39,753,000 | 44,418,000 | 57,495,000 | 55,949,000 | 55,949,000 | 55,949,000 | 53,683,000 | 47,166,000 | 40,721,000 | 34,418,000 | 24,737,000 | 19,307,000 | 12,880,000 | 8,550,000 | 8,894,000 | 10,500,000 | - | 11,308,000 | 7,849,000 | 7,432,000 |
| Earnings Before Taxes | 19.4% | -885,019,000 | -1,098,527,000 | -689,963,000 | -710,546,000 | -502,035,000 | -355,701,000 | -418,948,000 | -485,544,000 | -634,040,000 | -703,081,000 | -553,065,000 | -599,572,000 | -529,269,000 | -654,698,000 | -713,880,000 | -620,562,000 | -571,529,000 | -403,945,000 | -362,610,000 | -246,776,000 | -215,432,000 |
| EBT Margin | 100.0% | - | -1.13 | -0.74 | -0.81 | -0.60 | -0.46 | -0.60 | -0.75 | -1.06 | -1.23 | -1.02 | -1.21 | -1.18 | -1.61 | -1.87 | - | - | - | - | - | - |
| Net Income | 18.6% | -907,677,000 | -1,115,218,000 | -703,488,000 | -716,225,000 | -506,631,000 | -356,555,000 | -418,780,000 | -486,116,000 | -634,471,000 | -703,886,000 | -554,128,000 | -600,514,000 | -530,341,000 | -655,924,000 | -715,075,000 | -620,267,000 | -570,334,000 | -403,198,000 | -361,918,000 | -245,021,000 | -216,362,000 |
| Net Income Margin | 100.0% | - | -1.14 | -0.75 | -0.82 | -0.61 | -0.47 | -0.60 | -0.75 | -1.06 | -1.23 | -1.03 | -1.21 | -1.18 | -1.61 | -1.88 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -468,325,000 | -356,170,000 | -287,346,000 | -347,721,000 | -386,868,000 | -481,662,000 | -653,275,000 | -783,194,000 | -794,926,000 | 25,264,000 | 47,357,000 | 233,986,000 | 265,072,000 | -516,094,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 2.2% | 3,126 | 3,060 | 3,128 | 3,156 | 2,997 | 3,056 | 3,148 | 2,662 | 2,759 | 2,765 | 2,985 | 2,781 | 2,883 | 2,947 | 1,823 | 1,702 | 1,748 | 1,964 | 1,642 | 1,183 | 1,247 |
| Current Assets | -0.6% | 2,473 | 2,488 | 2,558 | 2,626 | 2,469 | 2,531 | 2,604 | 2,185 | 2,265 | 2,271 | 2,485 | 2,323 | 2,459 | 2,547 | 1,469 | 1,362 | 1,427 | 1,671 | 1,426 | 1,012 | 1,139 |
| Cash Equivalents | -2.3% | 852 | 872 | 967 | 1,039 | 869 | 1,234 | 2,116 | 1,599 | 1,697 | 1,482 | 1,503 | 1,475 | 1,640 | 1,764 | 835 | 725 | 809 | 732 | 371 | 210 | 410 |
| Inventory | 11.9% | 227 | 203 | 204 | 221 | 208 | 199 | 186 | 288 | 269 | 240 | 232 | 220 | 180 | 173 | 171 | 166 | 157 | 140 | 125 | 116 | 104 |
| Net PPE | 3.3% | 189 | 183 | 180 | 181 | 183 | 187 | 191 | 199 | 203 | 203 | 190 | 172 | 153 | 137 | 130 | 120 | 117 | 106 | 97.00 | 77.00 | 58.00 |
| Liabilities | 1.6% | 2,384 | 2,347 | 2,743 | 2,725 | 2,270 | 2,199 | 2,220 | 2,193 | 2,274 | 2,230 | 2,223 | 1,889 | 1,840 | 1,803 | 1,005 | 707 | 649 | 615 | 610 | 543 | 548 |
| Current Liabilities | -7.1% | 499 | 537 | 620 | 603 | 546 | 455 | 453 | 373 | 425 | 365 | 416 | 378 | 355 | 306 | 265 | 216 | 162 | 137 | 174 | 114 | 105 |
| Shareholder's Equity | 4.0% | 741 | 713 | 385 | 431 | 726 | 857 | 928 | 470 | 485 | 535 | 762 | 892 | 1,043 | 1,145 | 818 | 995 | 1,099 | 1,349 | 1,032 | 640 | 699 |
| Retained Earnings | -0.5% | -4,450 | -4,426 | -3,910 | -3,800 | -3,543 | -3,311 | -3,206 | -3,084 | -3,036 | -2,955 | -2,848 | -2,658 | -2,462 | -2,311 | -2,294 | -2,058 | -1,931 | -1,655 | -1,578 | -1,438 | -1,361 |
| Additional Paid-In Capital | 1.0% | 5,193 | 5,140 | 4,297 | 4,235 | 4,272 | 4,169 | 4,135 | 3,554 | 3,522 | 3,491 | 3,610 | 3,551 | 3,505 | 3,456 | 3,112 | 3,053 | 3,031 | 3,004 | 2,611 | 2,078 | 2,061 |
| Accumulated Depreciation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.00 | 38.00 | 33.00 | 28.00 | 25.00 | 22.00 |
| Shares Outstanding | 0.1% | 93.00 | 93.00 | 88.00 | 88.00 | 88.00 | 87.00 | 87.00 | 80.00 | 80.00 | 80.00 | 79.00 | 79.00 | 77.00 | 76.00 | 74.00 | 75.00 | 74.00 | 74.00 | 66.00 | 67.00 | 66.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -12.8% | -488 | -433 | -325 | -262 | -321 | -363 | -443 | -588 | -702 | -700 | 107 | 118 | 289 | 318 | -456 | -415 | -460 | -499 | -388 | -297 | -241 |
| Share Based Compensation | -22.7% | 190 | 245 | 233 | 212 | 189 | 115 | 114 | 114 | 114 | 113 | 108 | 101 | 94.00 | 86.00 | 79.00 | 69.00 | 60.00 | 56.00 | 50.00 | 45.00 | 40.00 |
| Cashflow From Investing | 155.5% | 138 | -248 | -1,046 | -1,059 | -1,058 | -447 | 495 | 374 | 408 | 53.00 | -121 | 19.00 | -52.78 | 134 | 287 | 32.00 | -13.53 | -221 | -370 | -626 | -438 |
| Cashflow From Financing | 1.7% | 335 | 329 | 233 | 771 | 560 | 564 | 562 | 339 | 352 | 366 | 682 | 612 | 595 | 584 | 643 | 907 | 881 | 900 | 530 | 516 | 922 |
SRPT Income Statement
2023-06-30Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues: | ||||
| Products, net | $ 238,988 | $ 211,237 | $ 470,483 | $ 400,062 |
| Type of Revenue [Extensible List] | us-gaap:ProductMember | us-gaap:ProductMember | ||
| Collaboration | 22,250 | 22,250 | $ 44,255 | $ 44,255 |
| Total revenues | 261,238 | 233,487 | 514,738 | 444,317 |
| Cost and expenses: | ||||
| Cost of sales (excluding amortization of in-licensed rights) | 34,124 | 37,795 | 69,141 | 69,238 |
| Research and development | 241,890 | 252,329 | 487,569 | 446,579 |
| Selling, general and administrative | 118,564 | 154,316 | 229,278 | 226,156 |
| Amortization of in-licensed rights | 179 | 179 | 357 | 357 |
| Total cost and expenses | 394,757 | 444,619 | 786,345 | 742,330 |
| Operating loss | (133,519) | (211,132) | (271,607) | (298,013) |
| Other loss, net: | ||||
| Gain from sale of Priority Review Voucher | 102,000 | 0 | 102,000 | 0 |
| Loss on debt extinguishment | 0 | 0 | (387,329) | 0 |
| Other income (expense), net | 16,934 | (16,961) | 29,641 | (34,226) |
| Total other (loss), net | 118,934 | (16,961) | (255,688) | (34,226) |
| Loss before income tax expense (benefit) | (14,585) | (228,093) | (527,295) | (332,239) |
| Income tax expense (benefit) | 9,355 | 3,388 | 13,400 | 4,267 |
| Net loss | (23,940) | (231,481) | (540,695) | (336,506) |
| Other comprehensive income (loss): | ||||
| Unrealized gains (losses) on investments, net of tax | (636) | (2,179) | 609 | (2,465) |
| Total other comprehensive income (loss) | (636) | (2,179) | 609 | (2,465) |
| Comprehensive loss | $ (24,576) | $ (233,660) | $ (540,086) | $ (338,971) |
| Net loss per share - basic | $ (0.27) | $ (2.65) | $ (6.11) | $ (3.85) |
| Net loss per share - diluted | $ (0.27) | $ (2.65) | $ (6.11) | $ (3.85) |
| Weighted average number of shares of common stock used in computing basic and diluted net loss per share | 88,743 | 87,511 | 88,466 | 87,383 |
| Weighted average number of shares of common stock used in computing basic and diluted net loss per share | 88,743 | 87,511 | 88,466 | 87,383 |
SRPT Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 851,929 | $ 966,777 |
| Short-term investments | 1,008,786 | 1,022,597 |
| Accounts receivable | 236,808 | 214,628 |
| Inventory | 226,876 | 203,968 |
| Other current assets | 148,215 | 149,891 |
| Total current assets | 2,472,614 | 2,557,861 |
| Property and equipment, net | 188,874 | 180,037 |
| Right of use assets | 134,728 | 64,954 |
| Non-current inventory | 166,635 | 162,545 |
| Other non-current assets | 163,039 | 162,969 |
| Total assets | 3,125,890 | 3,128,366 |
| Current liabilities: | ||
| Accounts payable | 109,796 | 95,875 |
| Accrued expenses | 326,877 | 418,996 |
| Deferred revenue, current portion | 44,989 | 89,244 |
| Other current liabilities | 16,992 | 15,489 |
| Total current liabilities | 498,654 | 619,604 |
| Long-term debt | 1,235,517 | 1,544,292 |
| Lease liabilities, net of current portion | 129,170 | 57,578 |
| Deferred revenue, net of current portion | 485,000 | 485,000 |
| Contingent consideration | 36,100 | 36,900 |
| Other non-current liabilities | 38 | 42 |
| Total liabilities | 2,384,479 | 2,743,416 |
| Commitments and contingencies (Note 16) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding | 0 | 0 |
| Common stock, $0.0001 par value, 198,000,000 shares authorized; 93,273,541 and 87,950,117 issued and outstanding at June 30, 2023, and December 31, 2022, respectively | 9 | 9 |
| Additional paid-in capital | 5,193,388 | 4,296,841 |
| Accumulated other comprehensive loss, net of tax | (1,055) | (1,664) |
| Accumulated deficit | (4,450,931) | (3,910,236) |
| Total stockholders’ equity | 741,411 | 384,950 |
| Total liabilities and stockholders’ equity | $ 3,125,890 | $ 3,128,366 |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.